CABAZITAXEL
| Brand name | JEVTANA KIT |
|---|---|
| Active ingredient | CABAZITAXEL |
| Strength | 60MG/1.5ML (40MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | June 2010 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12453712*PED | April 2031 | — |
| 8927592*PED | April 2031 | — |
| 10583110*PED | April 2031 | — |
| 10716777*PED | April 2031 | — |
| 12453712 | October 2030 | use U-4334 |
| 10583110 | October 2030 | use U-2753 |
| 10716777 | October 2030 | use U-2856 |
| 8927592 | October 2030 | use U-3200 |
| 7241907*PED | June 2026 | — |
| 7241907 | December 2025 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.